Loading...
Shanghai Junshi Biosciences Co., Ltd.
SHJBF•PNK
Healthcare
Biotechnology
$1.97
$0.00(0.00%)

Over the past four quarters, Shanghai Junshi Biosciences Co., Ltd. demonstrated steady revenue growth, increasing from $499.85M in Q4 2023 to $479.62M in Q3 2024. Operating income reached -$335.29M in Q3 2024, maintaining a consistent -70% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$292.04M, reflecting operational efficiency. Net income rose to -$281.81M, with EPS at -$0.29. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan